L18-MDP (100 μg; s.c.; single dose) has anti-infection effect in mice infected with Escherichia coli or Klebsiella pneumoniae[1].
L18-MDP (100 μg or 1000 μg; s.c., i.p., i.v. or p.o.; single dose) increases the survival rate of mice infected with Escherichia coli and improves the pathological tissue of mice infected with Listeria monocytogenes[1].
L18-MDP (100 μg or 200 μg; s.c. or i.p.; once daily for 3 days) increases the survival rate of mice infected with Candida albicans[1].
| Animal Model: | Mice infected with Escherichia coli, Klebsiella pneumoniae or Listeria monocytogenes[1]. |
| Dosage: | 100 μg or 1000 μg. |
| Administration: | Subcutaneous injection, intraperitoneal injection, intravenous injection or oral gavage; single dose. |
| Result: | Strengthened the phagocytosis of the microorganisms, weakened the virus activity, increased the survival rate and improved the pathological tissue. |
| Animal Model: | Mice infected with Candida albicans[1]. |
| Dosage: | 100 μg or 200 μg. |
| Administration: | Subcutaneous injection or intraperitoneal injection; once daily for 3 days. |
| Result: | Strengthened the phagocytosis of the microorganisms, weakened the virus activity, increased the survival rate and improved the pathological tissue. |
